Rapamycin suppresses experimental aortic aneurysm growth  by Lawrence, David M et al.
From the Society for Vascular Surgery
Rapamycin suppresses experimental aortic
aneurysm growth
David M. Lawrence, MD, Robert S. Singh, MD, David P. Franklin, MD, David J. Carey, PhD, and
James R. Elmore, MD, Danville, Pa
Objective: Inflammatory modulators are important in the pathogenesis of aneurysmal disease. Gene expression profiling
of experimental abdominal aortic aneurysm (AAA) tissue demonstrated upregulation of the FK506BP12 (rapamycin
binding protein) gene product. Rapamycin is a potent immunosuppressor that prevents recurrent stenosis. However, its
effect on aneurysm formation has not been studied. We therefore examined the effect of rapamycin in an experimental rat
AAA model.
Methods: Adult male Wistar rats underwent elastase infusion into isolated infrarenal aortas to create experimental
aneurysms. Rats were randomized to receive either rapamycin or placebo via gastric lavage daily starting on the day of
surgery. On postoperative day 7 the aneurysm was measured, the infrarenal aorta was harvested, and the rats were
euthanized. NFB was measured with Western blotting as a marker of inflammation. Matrix metalloproteinase (MMP)–9
protein levels were measured. Hematoxylin-eosin and elastin staining were used to examine tissue inflammation and
elastin preservation.
Results: Aneurysms were significantly smaller in diameter in the rapamycin-treated group (3.3 0.7 mm vs 4.5 0.5 mm;
P < .0001). NFB levels were significantly reduced by 64%  14% in rapamycin-treated aortas (P  .023). MMP-9 was
reduced in rapamycin-treated aortas by 54%  22% (P  .043). Hematoxylin-eosin and elastin staining showed no
changes in inflammatory infiltrate or degradation of elastin fibers in elastase-infused aortic segments in rapamycin-treated
rats.
Conclusion: Rapamycin significantly reduces the rate of aneurysm expansion in the experimental AAA rat model by 40%.
Biochemical evidence suggests that this is related to suppression of inflammatory signaling and decreased MMP-9 levels.
Rapamycin could provide a new treatment for small aneurysms. (J Vasc Surg 2004;40:334-8.)
Clinical Relevance: Human aortic aneurysms are characterized histologically by an inflammatory infiltrate with severe
proteolytic destruction. Rapamycin is an immunosuppressive agent commonly used to control transplant rejection and
intimal hyperplasia by modulating the inflammatory cascade. In this experimental model rapamycin suppressed aneurysm
expansion, decreased NFB activation (a marker of inflammation), and decreased matrix metalloproteinase–-9 levels. It
is hoped that rapamycin or other similar anti-inflammatory drugs will one day be able to control aneurysm expansion in
patientsOur research into the pathophysiology of abdominal
aortic aneurysms (AAAs) has focused on the inflammatory
cause of this disease. Research on modulating inflammation
could lead to development of medical interventions that
would benefit a subset of patients with small aortic aneu-
rysms. The goal of these treatments would be to stabilize
aneurysmal disease and prevent further expansion, thus
eliminating or delaying the need for surgery.
The rat aneurysm model is an established method of
creating experimental aortic aneurysms with porcine elas-
tase infusion. Aneurysm development in this rat model is
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doi:10.1016/j.jvs.2004.05.020334associated with production of inducible nitric oxide syn-
thase,1 increased matrix metalloproteinase–9 (MMP-9),1-3
an inflammatory infiltrate,3,4 and destruction of extracellu-
lar matrix.1-5 We performed initial investigations in our
laboratory into the differential gene expression associated
with aneurysm formation in the rat model using the Gene-
Chip expression analysis system (Affymetrix). One of the
genes upregulated in aneurysm formation was the rapamy-
cin binding protein FK506BP12 (unpublished data). This
led to our interest in rapamycin and its effect on aortic
aneurysms.
Rapamycin binding protein has been extensively stud-
ied in animal models and in human beings for its role in
intimal hyperplasia. Rapamycin has been recognized as an
important agent in vascular remodeling.6-8 More recently it
has become available for clinical use as an agent for coating
coronary stents to reduce the incidence of intimal hyper-
plasia.9-12 Evidence suggests that the primary mechanism
involves its effect on smooth muscle cell migration and
proliferation.13 To our knowledge rapamycin has not been
studied in aneurysmal disease. The known effects of rapa-
mycin on vascular tissues, the inflammatory cause of aortic
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binding protein in experimental aneurysms prompted us to
investigate the effects of rapamycin on experimental AAA
formation.
METHODS
Animal surgery. After obtaining appropriate approval
by the Institutional Animal Care and Use Committee, adult
male Wistar rats (275-400 g) underwent surgery with the
assistance of a stereo-operating microscope, as described by
Cartsen et al14 with modifications as explained below. After
induction of isoflurane anesthesia, a midline laparotomy
was performed. The aorta below the left renal vein was
carefully dissected away from the inferior vena cava, and
proximal and distal control was obtained. All lumbar
branches in this region were ligated. After securing proxi-
mal and distal ties a mattress stitch was placed in the
anterior aorta. The isolated infrarenal aorta was then can-
nulated with a 27-gauge needle, and infused with 1 mL of
elastase solution for 1 hour with a microinfusion pump
(Harvard Apparatus). The needle was then removed, the
mattress stitch tied, and blood flow restored to the legs.
The fascia was sutured, and skin wounds were stapled. The
rats were recovered, individually housed, and provided with
standard rat chow and water ad lib. The rats underwent
repeat exploration on postoperative day 7. Measurements
of aortic diameter were made with an ocular micrometer
with 0.1-mm gradations at 10 power mounted on the
operating microscope. The aneurysmal segment was
clamped, and the micrometer was oriented with the region
of maximal diameter perpendicular to the gradations. Ani-
mal care complied with the Guide for the Care and Use of
Laboratory Animals, Institute of Laboratory Animal Re-
sources, Commission on Life Sciences, and National Re-
search Council.
Aortic infusion and drug administration. All rats
received aortic infusion of 7 units of elastase (Sigma, Prod-
uct No. E-1250, Lot 102K7685, unit activity determined
by succinyl-Ala-Ala-Ala-p-nitroanalide as substrate) in
aqueous suspension to induce aneurysm formation. Rats
were randomized by animal care personnel into experimen-
tal (n 20) and control (n 18) groups. The surgeon was
blinded to the randomization. All treatments were started
preoperatively on the day of the operation, and were ad-
ministered via gastric lavage with an animal feeding needle
(Popper & Sons). The control group received tap water (1
mL/kg/d), and the treatment group received rapamycin
(Rapamune, Wyeth-Ayerst Laboratories; 1 mg/kg/d).
This dose was selected on the basis of published work in a
porcine model.13 Dosing was repeated daily until harvest.
All rats were euthanized on postoperative day 7 after repeat
exploration. Measurements of maximal aortic diameter
were recorded before elastase infusion, immediately after
elastase infusion, and before aortic harvest on postoperative
day 7. Rats that did not survive to harvest were excluded,
and the randomization schedule was adjusted by animal
care personnel. All harvested aortic segments were flash-frozen in liquid nitrogen. Individual specimens were then
selected for later histologic or biochemical analysis.
Elastin and hematoxylin or eosin staining. Aortic
segments were fixed with 10% formalin solution and im-
bedded in paraffin. BBC Harris hematoxylin and Harleco
1% alcoholic eosin Y staining was performed with a standard
protocol in 5 control and 6 rapamycin-treated specimens.
For the elastin staining Verhoeff elastic stain was used, with
a standard protocol in 5 control and 6 rapamycin-treated
specimens. The slides were viewed with a Zeiss microscope
equipped with a digital camera. Inflammation was evalu-
ated with hematoxylin or eosin stain. Elastin-stained sec-
tions were evaluated for qualitative changes and elastin loss.
The slides were further evaluated by 3 independent observ-
ers blinded to the treatment groups. For inflammation a
scale of 1 to 4 was used, with 1 indicating no inflammation
and 4 indicating severe inflammation. For elastin scoring an
analog scale of 1 to 4 was used, with 1 equal to less than
25% elastin remaining and 4 equal to greater than 75%
elastin remaining.
Western blot analysis. Abdominal aortas from rapa-
mycin-treated and control rats were placed in triton-X
extraction buffer. A 10% sodium dodecylsulfate–polyacryl-
amide gel electrophoresis was run overnight at 40 V, fol-
lowed by transfer to polyvinylidene difluoride (PVDF)
membrane at 70 V. Blots were blocked for 1 hour with 2%
nonfat powdered milk, sectioned, and incubated with ap-
propriate primary antibodies for 1 hour. Primary antibodies
used included NFB p65 rabbit polyclonal 1:500 (Santa
Cruz Biotechnology) and MMP-9 Ab-5 (92 kDa collage-
nase IV) mouse monoclonal 1:250 (Lab Vision Corpora-
tion). In addition, all blots were incubated with anti-actin
1:750 (Sigma). The blots were then incubated for 30
minutes in the appropriate secondary antibody. A digital
camera was used for chemiluminescence detection with the
Lumiimager (Boehringer Mannheim). Actin levels were
used to standardize protein loading, with the assumption
that the level of actin would be similar in all aortic speci-
mens. Protein levels for NFB and MMP-9 in rapamycin-
treated tissue extracts were calculated as a percentage of the
values for control tissue.
Functional NFB assay. Aortic segments were sub-
jected to further analysis for the presence of NFB activity
with a functional protein assay. Rat aneurysm segments
were homogenized and centrifuged, and the supernatant
was used for analysis. Nuclear extracts were prepared, and
the protein concentrations were determined with a Brad-
ford-based assay. Next an assay was performed with a Trans
Am NFB kit (Active Motif North America, Product No.
40096). Cell extract (2-20 g) and binding buffer were
added to a 96-well plate in which the oligonucleotide
containing the NFB consensus sequence is immobilized.
The samples were incubated for 1 hour with mild agitation
to enable the activated NFB to bind its consensus se-
quence. The samples were subsequently incubated with the
primary antibody, followed by the secondary antibody,
each for 1 hour. The developing solution was then added,
and the samples were incubated for 7 minutes, protected
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optical density was then read on a spectrophotometer
within 5 minutes at 450nm, with a reference wavelength of
655 nm.
Statistical analysis. Statistical analysis was performed
with Microsoft Excel 2000 for Windows. Data are reported
as mean  SEM. Continuous data were analyzed with the
Student t test. Noncontinuous data were analyzed with a 2
test. P  .05 was considered statistically significant. Histo-
logic grading with an ordinal scale was analyzed with a
repeated measures generalized estimating equation model
for multinomial data.
RESULTS
Aneurysm size. All rat aortas were infused with elas-
tase to induce AAA formation. The animals were randomly
assigned to receive either rapamycin or water via gastric
lavage. A total of 38 rats survived to postoperative day 7,
when the animals were euthanized. Perioperative mortality
was 25% in rapamycin-treated rats and 26% in control rats
(P  .83). The cause of death in all but 3 animals was hind
limb ischemia, requiring early euthanasia per our animal
protocol. There were 20 rats in the rapamycin-treated
group and 18 rats in the control group. The pre-infusion
aortic sizes in control rats (1.5  0.1 mm) and rapamycin-
treated rats (1.5  0.1 mm) were not statistically different
(P  .5). Immediate post-infusion diameters were also
similar between control and experimental animals (2.5 
0.3 mm vs 2.5  0.3 mm; P  .7). The pre-infusion and
post-infusion diameter in all rats was significantly different
Fig 1. Differential aneurysm growth. Aortic diameters for control
rats and rapamycin-treated rats before elastase infusion, immedi-
ately after elastase infusion, and on postoperative day 7. Rapamycin
significantly inhibited aneurysm expansion on postoperative day 7.
Aneurysmal expansion was 40% less in rapamycin-treated aortas
compared with control rats (P  .0001).(1.5 0.1 mm vs 2.5 0.1 mm; P .0001). This suggests
adequate distention with infusion of elastase. At laparot-
omy on postoperative day 7 aortic diameter was statistically
different between groups (Fig 1). Control rats had a mean
aortic size on postoperative day 7 of 4.5  0.5 mm, and
rapamycin-treated rats had a mean aortic size of 3.3  0.8
mm (P  .0001). This represents a 40% decrease in aneu-
rysmal expansion compared with the expansion seen in
control rats.
Elastin and hematoxylin or eosin staining. Elastin
staining revealed variable levels of aortic media destruction,
with separation, derangement, and fracturing of elastin
fibers in control and rapamycin-treated groups. Quantita-
tive analysis of elastin degradation showed no significant
difference in elastin preservation (P  .73).
Hematoxylin-eosin staining of control and rapamycin-
treated rats revealed marked inflammatory response. Quan-
titative analysis showed no significant difference in inflam-
matory cell infiltration (P  .28).
Western blot analysis. Protein staining for NFB
demonstrated decreased levels of staining in the rapamycin
group (Fig 2). NFB protein levels were decreased by 64%
 14% compared with controls (P .023). Protein staining
for MMP-9 also showed significantly decreased levels in
rapamycin-treated tissue (Fig 3). MMP-9 levels were de-
creased by 54%  22% versus controls (P  .042).
Functional protein assay. A functional assay for
NFB activity identified decreased levels of active NFB in
rapamycin-treated tissue (Fig 4). There was a 58% decrease
in NFB activity in rapamycin-treated tissue compared with
controls (0.187  0.11 vs 0.45  0.19; P  .014).
DISCUSSION
The development of an effective medical therapy to
slow the growth of aortic aneurysmal disease could be of
significant benefit to many patients with small AAAs. The
pathophysiology of human AAA formation is complex,
involving multiple factors, such as biomechanical wall
stress, inflammation, proteolytic degradation, and genet-
ics.3,15 Aneurysm production in the rat model is also mul-
tifactorial, depending not on elastolytic activity of the infu-
sate but on inflammatory modifiers and subsequent
proteolytic degradation.14
In this study rapamycin suppressed the growth of an-
eurysmal expansion by 40% compared with growth in con-
trol aortas. This occurred despite the observation that
Fig 2. Western blot analysis for NFB. Quantified protein levels
for NFB are statistically less in rapamycin-treated tissue (n  5)
compared with control tissue (n 5). NFB levels are decreased in
rapamycin-treated tissue by 64% (P .023).
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Our laboratory16 previously identified predominantly
MAC-1–positive staining cells in rat AAA tissue, indicating
an infiltrate composed of macrophages. Recent work has
also highlighted the importance of CD4 T cells in exper-
imental aneurysm formation.17 Rapamycin treatment did
cause reduced steady state levels of NFB and NFB acti-
vation in experimental aneurysms. This suggests that rapa-
mycin blocks a specific step in the inflammatory signaling
cascade.
In our study we observed a high degree of variability in
elastin destruction in elastase-infused aortas. There was no
significant effect of rapamycin treatment on elastin preser-
vation, as determined at histologic analysis. Previously we
reported a lack of correlation between elastin preservation
and aneurysm size in this model.14 While elastin destruc-
tion likely has an important role in aneurysm formation,
other tissue remodeling events are probably important.
Rapamycin is a macrolide antibiotic with potent anti-
fungal, immunosuppressive, and antimitotic properties. It
inhibits interleukin (IL)–2–stimulated lymphocyte activa-
tion and prevents intimal hyperplasia in allograft vessels.8
Thus rapamycin has been used in the transplant population
to avert the vasculopathy common with organ rejection.
The mechanism is thought to affect growth factor–related
smooth muscle cell (SMC) migration and proliferation,
resulting in reduced intimal hyperplasia and thrombosis. In
vitro studies have also confirmed the ability of rapamycin to
inhibit SMC proliferation in a balloon injury model. Poon
et al13 showed that in SMC cultures that rapamycin binds
to the cytosolic protein FK506BP12. It then complexes
with the mammalian target of rapamycin. When mamma-
lian target of rapamycin is bound, the G1/S phase transi-
tion in SMC division is blocked and SMC proliferation and
migration are inhibited.
NFB is a nuclear transcription factor thought to be
one of the primary modulators of inflammatory signaling.18
In these experiments NFB expression was decreased by
64% in rapamycin-treated AAA tissue. This was confirmed
with a functional assay that measured the unbound and
active NFB, which was decreased by 58% in the rapamy-
cin-treated tissue compared with control tissue. Inactive
NFB is bound by its inhibitor IB. When phosphorylated,
IB dissociates from NFB. The active form of NFB can
then translocate to the nucleus and stimulate gene tran-
scription.19 It is implicated in cell cycle progression20 and
in regulating vascular SMC proliferation, and is elaborated
Fig 3. Western blot analysis for matrix metalloproteinase
(MMP)–9. MMP-9 is identified in both control tissue (n 6) and
rapamycin-treated tissue (n  9). MMP-9 levels are decreased in
rapamycin-treated tissue by 54% (P  .043).in response to vascular injury. NFB is present in athero-
sclerotic lesions, is associated with intimal hyperplasia,21
and has been demonstrated in rat SMCs after balloon
injury.21 It can stimulate the production of multiple proin-
flammatory compounds, including inducible nitric oxide
synthase and IL-1. Furthermore, NFB is induced by var-
ious cytokines, particularly IL-1	 and tissue necrosis fac-
tor–
.20,21
Recently Nakashima et al22 demonstrated decreased rat
experimental aneurysm expansion through inhibition of
NFB using a decoy oligodeoxynucleotide. They also
noted NFB-positive adventitial macrophages in harvested
human aneurysm tissue. From these observations they con-
cluded that NFB has an important role in AAA pathophys-
iology. Our own results confirm the importance of NFB in
AAA development, and identify NFB as an important
target for rapamycin in aneurysm suppression.
Inhibition of NFB has been associated with decreased
production of MMP-9.23 In these experiments rapamycin
treatment resulted in MMP-9 levels decreased by 54%, and
was associated with suppression of aneurysms. In previous
studies with doxycycline, indomethacin, and specific MMP
inhibitors, such as BB-94, inhibition of MMP-9 activity in
the rat aneurysm model resulted in a decrease in aneurysm
size.16,24,25 Furthermore, Waller et al7 showed that rapa-
mycin inhibits expression of MMP-9 after arterial injury.
The effect of rapamycin on rat AAAs may be multifactorial,
inhibiting both anti-proteolytic and anti-inflammatory
mechanisms, suggesting that these components of aneu-
rysm formation are tightly interconnected.
CONCLUSION
Rapamycin, a known immunomodulator, suppresses
aneurysm expansion in the experimental rat model. Our
results suggest that inhibition of inflammatory signaling
mediated by NFB is the predominant mechanism for
suppression of aneurysm formation by rapamycin. NFB
Fig 4. NFB Functional assay. A functional assay for NFB activ-
ity demonstrated significantly less NFB in rapamycin-treated
tissue (n 8) compared with control tissue (n 5). NFB activity
as measured by optical density was 58% less in rapamycin-treated
aneurysms (P  .014).
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rapamycin. MMP-9 levels are also significantly decreased by
rapamycin. Further study to define these mechanisms could
lead to improved understanding of these agents and ulti-
mately lead to a promising medical therapy to prevent
expansion of AAA in human beings.
We thank Greg Notz and Alicia Duceman for assistance
in performing protein analysis and cell staining experi-
ments.
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